Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.42 |
| ▸ | ITGAV | P06756 | 14/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474456 | 0.96 | ITGB3 (0.42) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL7304338 | 0.92 | ITGB3 (0.40) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL6483064 | 0.89 | ITGB3 (0.43) | ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL7301850 | 0.88 | ITGB3 (0.39) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL6480916 | 0.86 | ITGB3 (0.47) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL6474409 | 0.83 | ITGB3 (0.46) | ITGB3ITGA2BITGAVSMN1; SMN2 | |
| SCHEMBL7306172 | 0.82 | ITGB3 (0.40) | ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL7301488 | 0.79 | ITGB3 (0.43) | ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL6485142 | 0.74 | ITGB3 (0.44) | ITGB3ITGA2BITGAV | |
| SCHEMBL7422874 | 0.72 | ITGB3 (0.47) | ITGB3ITGA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | claimed |
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
| EP-0854140-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | ITGB3 173/4885ITGA2B 100/4885ITGAV 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.